- Inherited thrombophilia and gestational venous thromboembolismJacqueline Conard
Hemostasis Thrombosis Unit of the Department of Biological Hematology, Hotel Dieu Hospital, Paris, France
Semin Thromb Hemost 29:131-42. 2003..In contrast, prophylaxis in the antepartum period is often determined on an individual basis. We give some indications of the appropriate prophylaxis on the basis of the ACCP recommendations and personal experience...
- [Thrombophilia and pregnancy: who should be tested? Which tests should be performed? The biologist point of view]Jacqueline Conard
Unité hémostase thrombose, Hotel Dieu, 1, Place du Parvis Notre Dame, 75181 Paris Cedex 04
Ann Med Interne (Paris) 154:340-4. 2003..Tests to be performed are proposed and their interpretation depends on whether the patient is pregnant, receiving oral contraception or oral anticoagulants...
- Progestogen-only contraception in women at high risk of venous thromboembolismJacqueline Conard
Hemostasis and Thrombosis Unit, Hotel Dieu University Hospital, Parvis Notre Dame, 75131 Paris cedex 04, France
Contraception 70:437-41. 2004..8 (0.2-3.9)]. These reassuring results need to be confirmed in other prospective studies...
- Pregnancy-associated venous thromboembolism (VTE) in combined heterozygous factor V Leiden (FVL) and prothrombin (FII) 20210 A mutation and in heterozygous FII single gene mutation aloneMeyer Michel Samama
Hemostasis and Thrombosis Unit, Hotel Dieu Hospital, Paris, France
Br J Haematol 123:327-34. 2003..In women with the FII mutation alone, the low risk may not justify prophylaxis in the absence of previous VTE. In post partum, prophylaxis is indicated in all cases...
- Biochemistry and clinical pharmacology of new anticoagulant agentsMeyer Michel Samama
Service d Hematologie Biologique, Hopital Hotel Dieu de Paris, France
Pathophysiol Haemost Thromb 32:218-24. 2002..These single-targeted agents are challenging multi-targeted drugs (heparins and vitamin-K antagonists). Other drugs including orally active FXa direct inhibitors will probably enrich the armentarium of antithrombotic drugs...
- Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER studyMarianne Canonico
INSERM Unit 780, Cardiovascular Epidemiology Section, 16 Avenue Paul Vaillant Couturier, 94807 Villejuif Cedex, France
Circulation 115:840-5. 2007..Transdermal estrogen may be safer. However, currently available data have limited the ability to investigate the wide variety of types of progestogen...
- [Pregnancy, contraception and HRT and venous thromboembolism]Jacqueline Conard
Unités d hémostase thrombose et de gynécologie médicale, Hotel Dieu, Université René Descartes Paris
Rev Prat 57:759-66. 2007..The detection of high-risk women because of personal history of VTE, associated risk factors and/or thrombophilia should improve the clinical management and thrombosis prophylaxis, especially when hormonal treatments are prescribed...
- Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administrationCeline Straczek
INSERM, Cardiovascular Epidemiology Unit, Villejuif, France
Circulation 112:3495-500. 2005..Transdermal estrogen may be safe with respect to VTE. We investigated the impact of the route of estrogen administration on the association between a prothrombotic mutation (factor V Leiden or prothrombin G20210A mutation) and VTE risk...
- Antithrombin alfa in hereditary antithrombin deficient patients: A phase 3 study of prophylactic intravenous administration in high risk situationsAndreas Tiede
Hannover Medical School, Dept of Haematology, Haemostasis, Oncology and Stem Cell Transplantation, Germany
Thromb Haemost 99:616-22. 2008..In conclusion, this study suggests that antithrombin alfa is a safe and effective alternative to human plasma-derived AT for treating hereditary AT deficiency patients at high risk for thromboembolic events...
- Recurrence rate after a first venous thrombosis in patients with familial thrombophiliaCarla Y Vossen
Department of Clinical Epidemiology, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands
Arterioscler Thromb Vasc Biol 25:1992-7. 2005..We prospectively determined the recurrence rate after a first venous thrombotic event in patients with familial thrombophilia attributable to factor V Leiden or deficiencies of protein C, S, or antithrombin...
- [Pregnancy-associated venous thrombosis in women with hereditary heterozygous factor V Leiden and/or factor II gene mutations]Meyer Michel Samama
Unité Hémostase et Thrombose Hôtel Dieu 1 Place du Parvis Notre Dame 75181 Paris cedex 04
Bull Acad Natl Med 188:1377-93; discussion 1393-6. 2004..In the post-partum period, there is a consensus on the use of LMWH for 6 weeks in women with single or dual mutations associated with thrombophilia...
- Antithrombin 'DREUX' (Lys 114Glu): a variant with complete loss of heparin affinityAlec Mushunje
Department of Haematology, University of Cambridge, Institute of Medical Research, UK
Thromb Haemost 88:436-43. 2002..However, no change in fluorescence was detected for the variant when titrated with heparin or the heparin pentasaccharide, nor was there detectable activation towards factor Xa, indicating a complete loss of heparin binding...
- Effects of oral and transvaginal ethinyl estradiol on hemostatic factors and hepatic proteins in a randomized, crossover studyRegine Sitruk-Ware
Center for Biomedical Research, Population Council, New York, NY 10021, USA
J Clin Endocrinol Metab 92:2074-9. 2007..Evaluation of the impact of delivery route on these changes is difficult due to an interaction between EE and the progestin component...
- Prothrombin 20210G>A is an ancestral prothrombotic mutation that occurred in whites approximately 24,000 years agoAriella Zivelin
The Amalia Biron Research Institute of Thrombosis and Hemostasis, Chaim Sheba Medical Center, Tel Hashomer 52621, Israel
Blood 107:4666-8. 2006....
- Hemostasis and menstruation: appropriate investigation for underlying disorders of hemostasis in women with excessive menstrual bleedingPeter A Kouides
Mary M Gooley Hemophilia Treatment Center, University of Rochester School of Medicine, Rochester, New York, USA
Fertil Steril 84:1345-51. 2005..This review highlights important components in a structured history and outlines primary and secondary hematologic testing that should be considered in the evaluation of excessive menstrual bleeding...
- Inhibitors and activation markers of the haemostatic system during hormone therapy: a comparative study of oral estradiol (2 mg)/ dydrogesterone and estradiol (2 mg)/ trimegestoneLucy A Norris
Department of Obstetrics and Gynaecology, Trinity Centre for Health Sciences, St James s Hospital, Dublin 8, Ireland
Thromb Haemost 100:253-60. 2008..This suggests an enhanced fibrinolytic response in this group. Further studies are required to determine the significance of this finding with respect to venous thrombosis risk...